JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us
このページは機械翻訳されています。他のページは英語で表示される場合があります。 View in English

Mycobacterium tuberculosisは,HIV-TB共感染の個体において,末期的なCD4+とCD8+のT細胞の拡張を調節する

  • 0Molecular Immunology Laboratory, Department of Immunopathology, Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh 160012, India.
Pathogens (basel, Switzerland) +

|

2025年8月28日

|

2025年8月28日

PubMedで要約を見る

まとめ

この要約は機械生成です。

結核の併発はHIV感染者の免疫力低下を悪化させる. 免疫チェックポイント分子 (ICM) をターゲットにすることで,これらの患者の臨床結果が改善される可能性があります.

科学分野

  • 免疫学
  • 感染症
  • HIV/AIDSに関する研究

背景

  • 結核 (Mycobacterium tuberculosis) は,HIV感染者 (PLWH) に共通する共感染です.
  • この共感染は罹病率と死亡率を悪化させるが,免疫メカニズムは完全に理解されていない.

研究 の 目的

  • 適応免疫反応の調節における Mycobacterium tuberculosis 感染症の役割を調査する.
  • HIV-Mtb の共感染者における5つの免疫チェックポイント分子 (ICM) の発現を調べる.

主な方法

  • 北インドの治療先のヒトコホートに関する横断的な研究
  • グループには,PLWH,Mtb感染者,HIV-Mtb共感染者,および健康な対照群が含まれています.
  • これらのICMのTIM-3,LAG-3,PD-1,CTLA-4およびT細胞表面表現の評価

主要な成果

  • HIV- Mtbの併感染者において,TIM-3,LAG-3,PD-1,CTLA-4の遺伝子発現が著しく増加した.
  • 2つのICMの共発を含む,TIM-3,CTLA-4,LAG-3を発現するCD4+およびCD8+T細胞の高頻度
  • ICMを発現する細胞の頻度は,CD4+T細胞数とプラズマのウイルス負荷と逆相関しており,HIVの進行と関連していることを示している.

結論

  • ミコバクテリア結核の併感染は,HIV感染者の免疫力低下を悪化させる.
  • 免疫チェックポイント分子 (ICM) を阻害剤 (ICI) で標的化することは,共感染患者の管理に有望である.

キーワード:

関連する概念動画

Pulmonary Tuberculosis I 01:29

321

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pulmonary Tuberculosis II 01:28

343

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Pulmonary Tuberculosis V 01:28

237

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Pulmonary Tuberculosis IV 01:26

202

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Pulmonary Tuberculosis III 01:31

439

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

• Class zero: The individual has no known TB exposure and has a negative tuberculin skin test.


• Class one: The individual has been exposed to...